- Home
- Publications
- Publication Search
- Publication Details
Title
PM00104 (Zalypsis®): A Marine Derived Alkylating Agent
Authors
Keywords
-
Journal
MOLECULES
Volume 19, Issue 8, Pages 12328-12335
Publisher
MDPI AG
Online
2014-08-15
DOI
10.3390/molecules190812328
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis
- (2014) Victoria Moneo et al. BMC CANCER
- Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen
- (2014) Daniel E. Castellano et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors
- (2014) Ramón Salazar et al. INVESTIGATIONAL NEW DRUGS
- A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
- (2013) J. Capdevila et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors
- (2013) Robin L. Jones et al. INVESTIGATIONAL NEW DRUGS
- Phase II study of weekly PM00104 (ZALYPSIS®) in patients with pretreated advanced/metastatic endometrial or cervical cancer
- (2013) Lainie P. Martin et al. MEDICAL ONCOLOGY
- First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
- (2012) T A Yap et al. BRITISH JOURNAL OF CANCER
- Population Pharmacokinetic–Pharmacodynamic Analysis of Neutropenia in Cancer Patients Receiving PM00104 (Zalypsis®)
- (2012) Mario González-Sales et al. CLINICAL PHARMACOKINETICS
- Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors
- (2012) Christophe Massard et al. INVESTIGATIONAL NEW DRUGS
- Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response
- (2011) E. Colado et al. HAEMATOLOGICA
- Chromone and Flavonoid Alkaloids: Occurrence and Bioactivity
- (2011) Shahriar Khadem et al. MOLECULES
- Molecular pharmacology and antitumor activity of Zalypsis ® in several human cancer cell lines
- (2009) Juan F.M. Leal et al. BIOCHEMICAL PHARMACOLOGY
- Zalypsis (PM00104) is a potent inducer of -H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition
- (2009) J. Guirouilh-Barbat et al. MOLECULAR CANCER THERAPEUTICS
- The present and future burden of urinary bladder cancer in the world
- (2009) Martine Ploeg et al. WORLD JOURNAL OF UROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now